Our company has been advancing the compatibility of the FLD series, which allows non-contact and non-invasive measurement of various indicators (biomarkers) including HbA1c, with a variety of devices.
We have now successfully developed a smartphone application capable of simultaneously measuring multiple parameters such as HbA1c, oxygen saturation, and pulse rate.
We are currently considering the optimal way to launch this product to the market, and plan to begin offering it on a limited basis to 10,000 to 20,000 users starting in June. Additionally, we are progressing towards a market launch in the EU region within this year.
Further details will be announced and released as needed from June onwards.